Antihypertensive effect of an enzymatic hydrolysate from Styela clava flesh tissue in type 2 diabetic patients with hypertension
Nutrition Research and Practice
; : 396-401, 2017.
Article
en En
| WPRIM
| ID: wpr-51183
Biblioteca responsable:
WPRO
ABSTRACT
BACKGROUND/OBJECTIVES: In this randomized, placebo-controlled, double-blind study, we evaluated the antihypertensive effects of enzymatic hydrolysate from Styela clava flesh tissue in patients with type 2 diabetes mellitus (T2DM) and hypertension. SUBJECTS/METHODS: S. clava flesh tissue hydrolysate (SFTH) (n = 34) and placebo (n = 22) were randomly allocated to the study subjects. Each subject ingested two test capsules (500 mg) containing powdered SFTH (SFTH group) or placebo capsules (placebo group) during four weeks. RESULTS: In the SFTH group, systolic and diastolic blood pressure decreased significantly 4 weeks after ingestion by 9.9 mmHg (P < 0.01) and 7.8 mmHg (P < 0.01), respectively. In addition, the SFTH group exhibited a significant decrease in hemoglobin A1c with a tendency toward improvement in homeostasis model assessment of insulin resistance, triglyceride, apolipoprotein B and plasma insulin levels after 4 weeks. No adverse effects were observed in other indexes, including biochemical and hematological parameters in both groups. CONCLUSION: The results of our study suggested that SFTH exerts a regulatory, antihypertensive effect in patients with T2DM and hypertension.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Apolipoproteínas
/
Plasma
/
Hidrolisados de Proteína
/
Triglicéridos
/
Presión Sanguínea
/
Resistencia a la Insulina
/
Cápsulas
/
Método Doble Ciego
/
Diabetes Mellitus Tipo 2
/
Ingestión de Alimentos
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
Nutrition Research and Practice
Año:
2017
Tipo del documento:
Article